ID   HaCaT
AC   CVCL_0038
SY   HaCAT; HACAT; Hacat
DR   BTO; BTO:0000552
DR   EFO; EFO_0002056
DR   CLDB; cl7229
DR   AddexBio; T0020001/117
DR   BCRJ; 0341
DR   CCRID; 3111C0001CCC000373
DR   CCRID; 3142C0001000001712
DR   ChEMBL-Cells; CHEMBL3308509
DR   ChEMBL-Targets; CHEMBL614392
DR   CLS; 300493/p800_HaCaT
DR   Cosmic; 1530737
DR   DSMZ; ACC-771
DR   GEO; GSE57080
DR   GEO; GSM913344
DR   GEO; GSM913345
DR   GEO; GSM960278
DR   GEO; GSM960279
DR   GEO; GSM960280
DR   GEO; GSM960286
DR   GEO; GSM960287
DR   GEO; GSM960288
DR   GEO; GSM960294
DR   GEO; GSM960295
DR   GEO; GSM960296
DR   GEO; GSM1375594
DR   GEO; GSM1375595
DR   GEO; GSM1375596
DR   GEO; GSM1375597
DR   GEO; GSM1375598
DR   GEO; GSM1375599
DR   GEO; GSM1375600
DR   GEO; GSM1375601
DR   GEO; GSM1375602
DR   GEO; GSM1375603
DR   GEO; GSM1375604
DR   GEO; GSM1375605
DR   GEO; GSM1861816
DR   GEO; GSM1861817
DR   GEO; GSM1861820
DR   GEO; GSM1861821
DR   GEO; GSM2112559
DR   GEO; GSM2112563
DR   GEO; GSM2495796
DR   GEO; GSM2495797
DR   GEO; GSM2495798
DR   IARC_TP53; 1820
DR   ICLC; HL14001
DR   KCB; KCB 200442YJ
DR   Lonza; 56
DR   MetaboLights; MTBLS127
DR   PRIDE; PXD000496
DR   PRIDE; PXD000670
DR   PRIDE; PXD002460
DR   PRIDE; PXD007789
DR   PRIDE; PXD013113
DR   TOKU-E; 3890
DR   Wikidata; Q5636366
RX   PubMed=2450098;
RX   PubMed=8162337;
RX   PubMed=8504475;
RX   PubMed=9290701;
RX   PubMed=9406811;
RX   PubMed=10523843;
RX   PubMed=11583982;
RX   PubMed=15389883;
RX   PubMed=20097197;
RX   PubMed=21269460;
RX   PubMed=21868764;
RX   PubMed=26989177;
RX   PubMed=29660373;
RX   PubMed=31629070;
CC   Sequence variation: Heterozygous for TP53 p.His179Tyr (c.535C>T) (ClinVar=VCV000127815) and p.Arg282Trp (c.843_844CC>TT) (PubMed=8504475).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Transcriptome analysis.
CC   Caution: Although HaCaT is distributed by a number of sources, the only official DKFZ-approved supplier is CLS.
CC   Discontinued: BCRJ; 0341; true.
CC   Discontinued: DSMZ; ACC-771; true.
CC   Discontinued: ICLC; HL14001; true.
CC   Derived from sampling site: Back; skin; epidermis; keratinocyte.
ST   Source(s): CCRID; CLS; DSMZ; PubMed=11416159; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 9,11
ST   D13S317: 10,12
ST   D16S539: 9,12
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 28,30.2 (CLS; PubMed=11416159)
ST   D21S11: 30.2 (CCRID)
ST   D2S1338: 17,25
ST   D2S441: 11
ST   D3S1358: 16
ST   D5S818: 12
ST   D6S1043: 12,19
ST   D7S820: 9,11
ST   D8S1179: 14
ST   FGA: 24
ST   Penta D: 11,13
ST   Penta E: 7,12
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 16,17
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   62Y
CA   Spontaneously immortalized cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 29
RX   PubMed=2450098; DOI=10.1083/jcb.106.3.761;
RA   Boukamp P., Dzarlieva-Petrussevska R.T., Breitkreutz D., Hornung J.,
RA   Markham A., Fusenig N.E.;
RT   "Normal keratinization in a spontaneously immortalized aneuploid human
RT   keratinocyte cell line.";
RL   J. Cell Biol. 106:761-771(1988).
RX   PubMed=8162337; DOI=10.1111/j.1600-0625.1993.tb00030.x;
RA   Schurer N., Kohne A., Schliep V., Barlag K., Goerz G.;
RT   "Lipid composition and synthesis of HaCaT cells, an immortalized human
RT   keratinocyte line, in comparison with normal human adult
RT   keratinocytes.";
RL   Exp. Dermatol. 2:179-185(1993).
RX   PubMed=8504475; DOI=10.1093/carcin/14.5.833;
RA   Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P.,
RA   Welsh J.A., Metcalf R.A., Stampfer M.R., Fusenig N.E., Rogan E.M.,
RA   Harris C.C.;
RT   "p53 mutations in human immortalized epithelial cell lines.";
RL   Carcinogenesis 14:833-839(1993).
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
RX   PubMed=9406811; DOI=10.1111/1523-1747.ep12340708;
RA   Henseleit U., Zhang J., Wanner R., Haase I., Kolde G., Rosenbach T.;
RT   "Role of p53 in UVB-induced apoptosis in human HaCaT keratinocytes.";
RL   J. Invest. Dermatol. 109:722-727(1997).
RX   PubMed=10523843; DOI=10.1038/sj.onc.1202934;
RA   Boukamp P., Popp S., Bleuel K., Tomakidi E., Burkle A., Fusenig N.E.;
RT   "Tumorigenic conversion of immortal human skin keratinocytes (HaCaT)
RT   by elevated temperature.";
RL   Oncogene 18:5638-5645(1999).
RX   PubMed=11583982; DOI=10.1016/S0002-9440(10)62541-2;
RA   Mueller M.M., Peter W., Mappes M., Huelsen A., Steinbauer H.,
RA   Boukamp P., Vaccariello M., Garlick J., Fusenig N.E.;
RT   "Tumor progression of skin carcinoma cells in vivo promoted by clonal
RT   selection, mutagenesis, and autocrine growth regulation by granulocyte
RT   colony-stimulating factor and granulocyte-macrophage
RT   colony-stimulating factor.";
RL   Am. J. Pathol. 159:1567-1579(2001).
RX   PubMed=15389883; DOI=10.1002/jcb.20212;
RA   Lemaitre G., Lamartine J., Pitaval A., Vaigot P., Garin J., Bouet S.,
RA   Petat C., Soularue P., Gidrol X., Martin M.T., Waksman G.;
RT   "Expression profiling of genes and proteins in HaCaT keratinocytes:
RT   proliferating versus differentiated state.";
RL   J. Cell. Biochem. 93:1048-1062(2004).
RX   PubMed=20097197; DOI=10.1016/j.yexcr.2010.01.020;
RA   Rasanen K., Vaheri A.;
RT   "Proliferation and motility of HaCaT keratinocyte derivatives is
RT   enhanced by fibroblast nemosis.";
RL   Exp. Cell Res. 316:1739-1747(2010).
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
RX   PubMed=26989177; DOI=10.1242/dev.133728;
RA   Elbediwy A., Vincent-Mistiaen Z.I., Spencer-Dene B., Stone R.K.,
RA   Boeing S., Wculek S.K., Cordero J., Tan E.H., Ridgway R.,
RA   Brunton V.G., Sahai E., Gerhardt H., Behrens A., Malanchi I.,
RA   Sansom O.J., Thompson B.J.;
RT   "Integrin signalling regulates YAP and TAZ to control skin
RT   homeostasis.";
RL   Development 143:1674-1687(2016).
RX   PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012;
RA   Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J.,
RA   Lobinski R., Chavatte L.;
RT   "Selenium-regulated hierarchy of human selenoproteome in cancerous and
RT   immortalized cells lines.";
RL   Biochim. Biophys. Acta 1862:2493-2505(2018).
RX   PubMed=31629070; DOI=10.1016/j.tiv.2019.104666;
RA   da Silva A.C.G., Chialchia A.R., de Castro E.G., e Silva M.R.L.,
RA   Arantes D.A.C., Batista A.C., Kitten G.T., Valadares M.C.;
RT   "A new corneal epithelial biomimetic 3D model for in vitro eye
RT   toxicity assessment: development, characterization and
RT   applicability.";
RL   Toxicol. In Vitro 62:104666-104666(2019).